Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Consensus Target Price from Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $55.60.

TARS has been the topic of several analyst reports. The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS opened at $48.11 on Friday. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.14. The company’s 50 day simple moving average is $50.92 and its 200 day simple moving average is $38.73. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -12.63 and a beta of 1.02. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Canada Pension Plan Investment Board purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter worth about $114,000. FMR LLC lifted its position in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after acquiring an additional 3,537 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after acquiring an additional 3,379 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Tarsus Pharmaceuticals by 64.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after acquiring an additional 2,879 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in Tarsus Pharmaceuticals in the second quarter valued at approximately $202,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.